화학요법 유발성 탈모(CIA) 치료 기기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 판매 형태별, 적응증별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Chemotherapy-induced Alopecia Treatment Device Market Growth & Trends:

The global chemotherapy induced alopecia treatment device market size is anticipated to reach USD 174.7 million by 2030 and is projected to grow at a CAGR of 14.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. The primary factors driving the market are increasing chemotherapy adoption, technological advancements, growing awareness & adoption, and government initiatives. In 2024, the American Cancer Society forecasts around 67,880 new cases of uterine cancer in the United States, with approximately 13,250 women expected to die from the disease. This significant number of cases highlights an ongoing need for effective treatment options, including chemotherapy-induced alopecia (CIA) treatment devices. As many of these patients undergo chemotherapy, there will be an increased demand for solutions that address hair loss, underscoring the importance of CIA treatment devices in supporting women through their cancer treatment journey

Advancements in chemotherapy-induced alopecia (CIA) treatment devices are driving the market growth. According to NCBI article published in March 2024, Cold capping, a non-pharmacologic approach to reducing chemotherapy-induced alopecia (CIA), is gaining recognition for its potential to preserve hair during treatment. A study reviewing the real-world effectiveness and tolerability of a manual cold capping system across diverse patient demographics found that 95% of the 100 patients who initiated cold capping completed the process. The median hair retention was reported at 75%, with 92.1% of patients achieving favorable results, defined as retaining 50% or more of their hair.

Chemotherapy-induced Alopecia Treatment Device Market Report Highlights:

• The manual cooling systems segment led the market with the largest revenue share of 52.7% in 2023, due to ongoing product advancements, growing initiatives by key companies, and increasing cancer prevalence
• Based on sales modality, the rental sales segment led the market with the largest revenue share of 80.9% in 2023. Growing patient awareness of scalp cooling systems has increased demand for rental options. As more individuals seek to mitigate chemotherapy-induced hair loss, healthcare providers are expanding their services to include rental programs, enhancing accessibility
• Based on indication, the breast cancer segment led the market with the largest revenue share of 66.9% in 2023. Rising incidence of breast cancer, technological advancement, and growing awareness drive the market growth
• Based on end use, the hospital segment led the market with the largest revenue share at 44.8% in 2023. Hospitals are integrating these CIA devices into their oncology departments to offer patients a proven method for mitigating chemotherapy-related hair loss
• North America dominated the market with the largest revenue share of 52.8% in 2023. Rising cancer cases, product launches, regulatory approvals, and advanced healthcare infrastructure drive North America's demand for CIA treatment devices

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Sales Modality
  • 1.2.3. Indication
  • 1.2.4. End Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecast timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity price analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product Segment
  • 2.2.2. Sales Modality Segment
  • 2.2.3. Indication Segment
  • 2.2.4. End Use Segment
  • 2.2.5. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Global Chemotherapy Induced Alopecia (CIA) Treatment Device Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising incidence of cancer
    • 3.2.1.2. Increasing prevalence of chemotherapy-induced alopecia
    • 3.2.1.3. Technological advancements
    • 3.2.1.4. Growing Awareness and Adoption
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Low product awareness
    • 3.2.2.2. Limited number of manufacturers
• 3.3. Chemotherapy Induced Alopecia (CIA) Treatment Device Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Chemotherapy Induced Alopecia (CIA) Treatment Device Market: Product Estimates & Trend Analysis

• 4.1. Chemotherapy Induced Alopecia (CIA) Treatment Device Market: Product Dashboard
• 4.2. Chemotherapy Induced Alopecia (CIA) Treatment Device Market: Product Movement Analysis
• 4.3. Chemotherapy Induced Alopecia (CIA) Treatment Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Manual Cooling Systems
  • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.5. Automated Cooling Systems
  • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Chemotherapy Induced Alopecia (CIA) Treatment Device Market: Sales Modality Estimates & Trend Analysis

• 5.1. Chemotherapy Induced Alopecia (CIA) Treatment Device Market: Sales Modality Dashboard
• 5.2. Chemotherapy Induced Alopecia (CIA) Treatment Device Market: Sales Modality Movement Analysis
• 5.3. Chemotherapy Induced Alopecia (CIA) Treatment Device Market Size & Forecasts and Trend Analysis, by Sales Modality, 2018 to 2030 (USD Million)
• 5.4. Rental Sales
  • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.5. Direct Sales
  • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Chemotherapy Induced Alopecia (CIA) Treatment Device Market: Indication Estimates & Trend Analysis

• 6.1. Chemotherapy Induced Alopecia (CIA) Treatment Device Market: Indication Dashboard
• 6.2. Chemotherapy Induced Alopecia (CIA) Treatment Device Market: Indication Movement Analysis
• 6.3. Chemotherapy Induced Alopecia (CIA) Treatment Device Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 6.4. Breast Cancer
  • 6.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 6.5. Prostate Cancer
  • 6.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 6.6. Ovarian Cancer
  • 6.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 6.7. Uterine Cancer
  • 6.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 6.8. Others
  • 6.8.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Chemotherapy Induced Alopecia (CIA) Treatment Device Market: End Use Estimates & Trend Analysis

• 7.1. Chemotherapy Induced Alopecia (CIA) Treatment Device market: End Use Dashboard
• 7.2. Chemotherapy Induced Alopecia (CIA) Treatment Device Market: End Use Movement Analysis
• 7.3. Chemotherapy Induced Alopecia (CIA) Treatment Device Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Hospitals
  • 7.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 7.5. Cancer Centers
  • 7.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 7.6. Outpatient Clinics
  • 7.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 8. Chemotherapy Induced Alopecia (CIA) Treatment Device Market: Regional Estimates & Trend Analysis by Country, Product, Indication, Sales Modality, & End Use

• 8.1. Global Chemotherapy induced alopecia (CIA) treatment device market: Regional Dashboard
• 8.2. Market Size & Forecasts Trend Analysis, 2018 to 2030
• 8.3. North America
  • 8.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.3.2. U.S.
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key country dynamics
    • 8.3.4.2. Regulatory framework/ reimbursement structure
    • 8.3.4.3. Competitive scenario
    • 8.3.4.4. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. UK market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. France market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.4.8. Norway
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Norway market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.4.9. Denmark
    • 8.4.9.1. Key country dynamics
    • 8.4.9.2. Regulatory framework/ reimbursement structure
    • 8.4.9.3. Competitive scenario
    • 8.4.9.4. Denmark market estimates and forecast, 2018 - 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.5.3. Japan
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. India market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.5.7. South Korea
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Regulatory framework/ reimbursement structure
    • 8.5.7.3. Competitive scenario
    • 8.5.7.4. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.7.3. South Africa
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ reimbursement structure
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. Kuwait market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Manufacturers
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2023
  • 9.3.4. Dignitana
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Paxman
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Penguin Cold Caps
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Chemotherapy Cold Caps, Inc.
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Aspen Systems, LLC's
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Cooler Heads Care, Inc.
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Arctic Cold Caps, LLC
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Stemtech Medical Devices
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. Polar Cold Caps LLC
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives